HC Wainwright Analysts Increase Earnings Estimates for JANX

Janux Therapeutics, Inc. (NASDAQ:JANX) – Equities researchers at HC Wainwright lifted their Q2 2026 earnings estimates for Janux Therapeutics in a research report issued to clients and investors on Monday, May 11th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.48) per share for the quarter, up from their previous forecast of ($0.59). The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Janux Therapeutics’ Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.52) EPS, FY2026 earnings at ($1.89) EPS, FY2027 earnings at ($2.44) EPS, FY2028 earnings at ($2.51) EPS and FY2029 earnings at ($1.00) EPS.

Several other equities research analysts have also recently commented on JANX. Wall Street Zen raised Janux Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, April 5th. Barclays downgraded shares of Janux Therapeutics from an “overweight” rating to an “underweight” rating and reduced their price objective for the stock from $29.00 to $14.00 in a research report on Monday, April 20th. Cantor Fitzgerald dropped their target price on shares of Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Weiss Ratings raised shares of Janux Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 22nd. Finally, UBS Group lowered Janux Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the company from $57.00 to $15.00 in a research report on Wednesday, April 15th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $45.85.

Janux Therapeutics Trading Up 1.3%

JANX stock opened at $14.41 on Wednesday. The firm has a market cap of $878.78 million, a PE ratio of -7.83 and a beta of 2.58. The stock has a 50-day moving average price of $14.39 and a 200-day moving average price of $17.18. Janux Therapeutics has a 1-year low of $12.12 and a 1-year high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.13. The firm had revenue of $3.73 million during the quarter, compared to analyst estimates of $4.36 million.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Nano Cap New Millennium Growth Fund L P purchased a new stake in Janux Therapeutics in the 4th quarter valued at $34,000. Caitong International Asset Management Co. Ltd purchased a new stake in Janux Therapeutics in the 4th quarter valued at about $51,000. Osaic Holdings Inc. lifted its position in shares of Janux Therapeutics by 704.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after buying an additional 3,037 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Janux Therapeutics by 175.5% during the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after acquiring an additional 2,502 shares during the period. Finally, Winthrop Capital Management LLC purchased a new position in Janux Therapeutics in the third quarter worth $106,000. Institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.